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Mitochondrial dynamicsThe etiology of motor neuron degeneration in amyotrophic lateral sclerosis (ALS) remains to be better
understood. Based on the studies from ALS patients and transgenic animal models, it is believed that ALS is
likely to be a multifactorial and multisystem disease. Many mechanisms have been postulated to be involved
in the pathology of ALS, such as oxidative stress, glutamate excitotoxicity, mitochondrial damage, defective
axonal transport, glia cell pathology and aberrant RNA metabolism. Mitochondria, which play crucial roles in
excitotoxicity, apoptosis and cell survival, have shown to be an early target in ALS pathogenesis and
contribute to the disease progression. Morphological and functional defects in mitochondria were found in
both human patients and ALS mice overexpressing mutant SOD1. Mutant SOD1 was found to be
preferentially associated with mitochondria and subsequently impair mitochondrial function. Recent studies
suggest that axonal transport of mitochondria along microtubules and mitochondrial dynamics may also be
disrupted in ALS. These results also illustrate the critical importance of maintaining proper mitochondrial
function in axons and neuromuscular junctions, supporting the emerging “dying-back” axonopathy model of
ALS. In this review, we will discuss how mitochondrial dysfunction has been linked to the ALS variants of
SOD1 and the mechanisms by which mitochondrial damage contributes to the disease etiology.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
characterized by preferential motor neuron death. Approximately 10–
20% of the cases are familial whereas the majority of them are
sporadic. Among the familial cases, themost common disease-causing
mutations are found in the copper–zinc superoxide dismutase (SOD1)
gene [1,2]. Mutations in other genes have also been found to cause
various subsets of familial ALS, including the recently discovered RNA
processing proteins TDP-43 [3,4] and FUS/TLS [5,6]. While the new
gene mutations in TDP-43 and FUS/TLS will help understanding the
etiology of ALS, particularly the potential mechanisms underlying
both sporadic and familial ALS, the large body of knowledge on the
disease pathogenesis has been based on the studies of mutant SOD1
mediated familial ALS in the past decade. This review is also focused
on the mitochondrial dysfunction induced by mutant SOD1.
The mitochondrion is a critical organelle within cells executing
multiple functions. Mitochondria are the primary site of ATP
production, maintain calcium homeostasis and participate in calcium
signaling, and regulate intrinsic apoptosis. Mitochondrial malfunction
confers pleiotropic effects to the cells, especially neurons with an
elevated susceptibility to aging and stress. Mitochondrial pathology isCellular Biochemistry, College
ne, Lexington, KY 40506, USA.
ll rights reserved.a key player among multiple working hypotheses in the ALS studies
[2,7]. Mutant SOD1 has been reported to be associated with
mitochondria, and the morphology and bioenergetic function of
mitochondria can consequently be impacted. More recent studies also
support that axonal transport of mitochondria is disrupted by mutant
SOD1 in ALS. Furthermore, mitochondrial dynamics and function can
be altered when the axonal transport in motor neurons is compro-
mised. The above mechanisms are not mutually exclusive, instead
may form a vicious cycle that deteriorates mitochondria in motor
neurons especially in the distal nerve terminals. These observations
suggest that mitochondrial dysfunction is likely an important causal
or contributing factor to ALS pathogenesis and progression. This
reviewwill discuss the ﬁndings and themechanistic insights garnered
from the studies.
2. Subcellular localization of SOD1
SOD1 is a ubiquitous protein that functions as a primary
antioxidant by catalyzing the disproportionation of superoxide
radicals to hydrogen peroxide and molecular oxygen. The homo-
dimeric protein is localized predominantly in the cytoplasm, but it is
also found in other cellular compartments including the nucleus [8],
endoplasmic reticulum [9] and mitochondria [10,11]. Wild type (WT)
SOD1 as well as copper chaperone for SOD1 (CCS) has been found in
the intermembrane space (IMS) of mitochondria [10,11]. It has been
proposed that the nascent SOD1 polypeptide with nometal ion bound
can efﬁciently enter the mitochondria and that the maturation of
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formation) inside mitochondria and the subsequent retention in IMS
involve the SOD1–CCS interaction. Moreover, high levels of CCS in
the mitochondrial intermembrane space could result in enhanced
mitochondrial accumulation of SOD1 [12].
The ALS-relatedmutant SOD1 proteins have also been found in the
IMS, matrix and outer membrane of mitochondria [13–16]. It is likely
that mutant SOD1 fails to fold properly and perturbs the physiological
regulation of mitochondrial import and retention [16]. However,
it remains unclear how mutant SOD1 becomes aggregated on the
outer membrane or in the matrix of mitochondria. It is also unclear
how mutant SOD1 is selectively recruited to spinal, but not liver,
mitochondria [17].
Once associated with mitochondria, the mutant SOD1 is believed
to cause multiple damages to mitochondria. An early event could be
damage to the mitochondrial membrane leading to loss of mitochon-
drial membrane potential and swelling of the important organelle
[18,19]. Potential consequences include impaired respiratory complex
[20–22], disrupted redox homeostasis and decreased ATP production
[23]. Furthermore, calcium homeostasis can be disrupted [22,24–26]
and apoptosis may be activated [27–29]. Details of the above inter-
related mechanisms underlying mutant SOD1 induced mitochondrial
dysfunction will be discussed in the sections in the ﬁrst half of this
review.
3. Abnormal mitochondrial morphology and bioenergetics in ALS
Early studies have shown degenerating mitochondrial vacuoles in
axons and dendrites of motor neurons in presymptomatic mice
expressing mutant SOD1 [18,19,30]. In addition, dense conglomerates
of mitochondria in the anterior horn of lumbar spinal cord and
proximal axons have been found in sporadic ALS patients [31,32].
Abnormal clustering of mitochondria was recently reported in motor
axons in mutant SOD1 transgenic mice [33]. Extensive fragmentation
of mitochondria was also reported in cultured NSC34 cells over-
expressing mutant SOD1 [34,35]. A further study found that
vacuolation of mitochondria in the spinal motor neurons of G93A
transgenic mice was caused by expansion of the IMS and the outer
mitochondrial membrane. The same study found that the degener-
ative vacuoles were bounded by mutant SOD1 that colocalized with
mitochondrial outer membrane markers [36]. Besides alteration of
mitochondrial morphology, damage to the mitochondrial membrane
caused by mutant SOD1 can yield loss of mitochondrial membrane
potential, disruption of mitochondrial respiratory chain activity
[20,21], and reduction in mitochondrial Ca2+ buffering capability
[26]. The dysregulation in electron transfer chain complexes was
observed in both G93A SOD1 transgenic mice and human ALS patients
[20,22].
4. Disruption of calcium homeostasis in ALS
Another important function of mitochondria is to buffer intracel-
lular surges of Ca2+ in excited cells. In excitable cells like motor
neurons, mitochondria play an important role in short-term handling
of rapid cytosolic Ca2+ transients. Ca2+ is a ubiquitous second
messenger and participates in many signaling pathways that are
crucial for cell survival. Increased Ca2+ concentration and mitochon-
drial damagewere found in ALS patients as well as animal and cellular
ALS models [25,26,37–39]. A signiﬁcant decrease in mitochondrial
Ca2+ loading capacity in brain and spinal cord, but not in liver, was
observed in presymptomatic G93A mutant transgenic mice [38].
Elevated Ca2+ can induce reactive oxygen species and oxidative stress
in primary motor neurons isolated from G93A transgenic mice [25].
Alternatively, Ca2+ mediated glutamate excitotoxicity might contrib-
ute to the mutant SOD1 toxicity in motor neurons. Altogether, the
mitochondrial dysfunction induced by mutant SOD1, disruptedcalcium homeostasis and subsequent excitotoxicity are likely to be
interrelated mechanisms that collectively contribute to motor neuron
degeneration in ALS.
5. Involvement of mitochondria-mediated apoptosis in ALS
Mitochondria-mediated apoptosis was found to be involved in
motor neuron degeneration in early studies of ALS. In G93A SOD1
transgenic mice, cytosolic release of cytochrome c was observed [27–
29], and levels of pro-apoptotic proteins Bad and Bax were increased
while those of anti-apoptotic proteins Bcl-2, Bcl-xL and XIAP were
decreased [40–42]. It has been proposed that mutant SOD1 can
sequester anti-apoptotic protein Bcl-2 [27], reduce mitochondrial
membrane potential, and trigger cytochrome c release from mito-
chondria [27–29]. Caspase-1 and caspase-3 were also found to be
sequentially activated in motor neurons and astrocytes in G93A SOD1
mice as well as in G37R SOD1 and G85R SOD1mice [43–45]. Strategies
intervening in mitochondria-mediated apoptosis were demonstrated
to be effective in G93A SOD1mice: (i) intraventricular administration
of minocycline, which inhibits cytochrome c release from mitochon-
dria, was shown to delay disease onset and extend survival [46]; (ii)
over-expression of anti-apoptotic protein Bcl-2 could delay activation
of the caspases, attenuate neuron degeneration and delay disease
onset and mortality [41,47]; and (iii) intraventricular administration
of a broad spectrum caspase inhibitor zVAD-fmk could delay disease
onset and mortality [43]. However, the clinical trials based on the
above apoptosis-inhibiting approaches (e.g., minocycline) failed in
human ALS patients [48].
Interestingly, Gould et al. crossed the mutant SOD1 transgenic
mice with Bax knockout mice and showed that neuromuscular
denervation and mitochondrial vacuolization persisted in the absence
of apoptotic death of motor neuron cell bodies in the double mutant
mice [49]. Neuromuscular denervation was observed to begin long
before the activation of apoptotic proteins, and Bax deﬁciency delayed
the onset of neuromuscular denervation. Motor neurons exhibited
mitochondrial abnormalities at the innervated neuromuscular junc-
tion at the onset of neuromuscular denervation. In addition,
presynaptic terminals of motor neurons accumulated high levels of
mutant SOD1 before the axons were withdrawn from the neuromus-
cular junction. A separate study showed denervation of 40%
neuromuscular junctions in pre-symptomatic G93A SOD1 transgenic
mice (47 days), 60% loss of ventral root axons in 80 days old G93A
mice (immediately prior to onset), and signiﬁcant motor neuron
death until 100 days old (post-symptomatic) [50]. The results from
these studies support the “dying back” hypothesis that clinical
symptoms in the G93A SOD1 mice result from damages to the distal
motor axon rather than the activation of the cell death pathway in cell
bodies. Furthermore, the results suggest that local mitochondrial
changes in distal axons may represent a triggering mechanism for
axonal degeneration and denervation. The ﬁndings inspired more
careful studies of mitochondrial abonormalities in ALS with respect to
the subcellular localization of such changes as well as the transport
and dynamics of mitochondria. The signiﬁcance and ﬁndings of
mitochondrial transport and dynamics in the context of ALS are
discussed below.
6. Disruption of axonal transport in ALS
Neurons have extensive dendritic arbors and axonal processes that
can extend far from the cell body. Transport of materials (proteins and
organelles) and signals between the cell body and neuronal processes
is crucial to neuronal function and survival. Disruption of slow axonal
transport of the cytoskeleton is one of the earliest pathological events
in mutant SOD1 mice [51,52]. Fast axonal transport mediated by
kinesin and dynein motor complexes is responsible for transporting
membrane-bound organelles (e.g., mitochondria) for axonal and
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protein kinesin (KIF5A) can cause spastic paraplegia [53] and
mutations in the retrograde motor complex dynein–dynactin cause
motor neuron degeneration in humans and mice [54,55]. Mouse
strains carrying various dynein or dynactin mutations also showed
retrograde transport impairment and motor neuron degeneration
[54,56–59]. Decreased kinesin-mediated (anterograde) and dynein-
mediated (retrograde) axonal transport have been observed both in
ALS patients and in transgenic animal models [51,60–65]. More
intriguingly, crossing of G93A SOD1 ALS mice with different mouse
strains carrying dynein or dynactin mutations resulted in various
degrees of protection in the double mutant mice [56–58,66,67].
Nevertheless, the results strongly support that axonal transport is
likely a critical component in ALS disease etiology.
The detailed mechanisms by which axonal transport is affected in
ALS have yet to be established. In the last few years, ALS-related
mutant SOD1 proteins have been shown to interact with both the
anterograde motor protein kinesin-2 complex via kinesin-associated
protein 3 (KAP3) and the retrograde motor protein complex dynein–
dynactin [68–70], providing potential molecular mechanisms how
mutant SOD1 may interfere with axonal transport. Most recently, a
genome-wide single nucleotide polymorphism analysis in a set of
1821 sporadic ALS cases and 2258 controls from the United States and
Europe revealed that a variant within the KAP3 gene was associated
with decreased KAP3 expression and increased survival in sporadic
ALS [71]. Examination of the literature revealed a report showing
increased expression of KAP3 in mutant SOD1 transgenic mice [72].
These ﬁndings provide an emerging concept that alterations of axonal
transport might be involved in both familial and sporadic ALS.7. Axonal transport of mitochondria and its regulation
Different from other transported organelles, mitochondria are
unique since they do not have a deﬁned destination. Their dynamics
are inﬂuenced by moment-to-moment changes in the energy
demands of the cell [73]. Appropriate distribution of mitochondria is
critical for meeting cellular energy demands or regulation of Ca2+
levels, especially in neurons [74]. Mitochondria are frequently found
in axon terminals due to the high demand of ATP and Ca2+ handling at
synapses [75,76]. In response to synaptic excitation, mitochondria
redistribute to the dendrites and facilitate spine morphogenesis and
synaptogenesis [77]. In neurons, mitochondria migrate in both
anterograde and retrograde directions through association with
kinesin and dynein motor complexes. Disruption of kinesin heavy
chain KIF5B causes perinuclear clustering of mitochondria in mouse
neurons, indicating that KIF5B is essential for mitochondrial disper-
sion [78]. In addition, other kinesin superfamily members KIF1B and
KLC3 are also implicated in anterograde transport of mitochondria
[79,80]. Dynein is important not only for axonal retrograde transport
of mitochondria but also for mitochondrial ﬁssion [81].
The precise mechanisms that regulate the kinesin and dynein
motor complexes and their attachment to the organelles are yet to be
fully understood [74]. One mechanism by which mitochondria are
attached to kinesin has been described. Milton is an adaptor protein
interacting with both kinesin heavy chain (KHC) and the mitochon-
drial protein Miro and recruits mitochondria to the kinesin motor in
microtubule-dependent transport [82–86]. The interaction between
Milton and KHC is independent of kinesin light chain (KLC). Miro
mutants in Drosophila cause enrichment of mitochondria in neuronal
somata and reduction in neuropil [84]. GTPase defective mutants of
Miro resulted in the aggregation of mitochondria [85]. The C-terminal
transmembrane domain within Miro is required for mitochondrial
outer membrane targeting. The N-terminus withinMiro is responsible
for binding with the kinesin-interacting protein GABA-A receptor-
interacting factor 1 (GRIF-1) and O-linked N-acetylglucosaminetransferase interacting protein 106 (OIP106), linking mitochondria
to kinesin-mediated axonal transport [87–89].
Miro contains two Ca2+-binding EF-hand motifs, providing a
calcium-responsive mechanism to regulate mitochondrial transport.
Ca2+ binding to the EF-handmotif of Miro can promote direct binding
of Miro to KHC rather than via Milton and prevent the attachment of
KHC to microtubules [86]. In response to excitation, an inﬂux of Ca2+
in both pre- and post-synaptic cytosol will consequently inhibit
mitochondrial transport. The locally arrested mitochondria are then
able to provide more ATP and to buffer high Ca2+ to avoid
overexcitement. Mitochondria subsequently move away when the
local Ca2+ concentration returns to normal and ATP is supplied
[90,91]. This provides a mechanism for responding to local calcium
homeostasis and energy demand.
Neurotrophic factors, which are critical to neuronal differentiation
and survival and axonal growth and maintenance, can also regulate
axonal transport of mitochondria. For instance, nerve growth factor
(NGF) has been shown to regulate the motility and distribution of
axonal mitochondria and cause the local accumulation of mitochon-
dria in cultured primary neurons [92,93].
8. Disruption of axonal transport of mitochondria in ALS
Disruption of mitochondrial transport has been implicated in
neurodegenerative diseases including ALS [74,94,95]. Mitochondria,
which display saltatory movement along microtubules, are trans-
ported by kinesin and dynein motors at the speed of approximately
1 μm/s (i.e., 86.4 mm/day). In one study using both primary neurons
isolated from G93A SOD1 transgenic mice and cortical neurons
transfected with G93A SOD1, mitochondrial transport was observed
to be selectively reduced in the anterograde direction [94]. In another
study using differentiated NSC34 cells overexpressing mutant SOD1,
mitochondrial transport was found to be altered in both anterograde
and retrograde directions [95].
The mechanism by which mutant SOD1 interferes with mitochon-
drial transport is yet to be elucidated. Several scenarios can be
envisioned and illustrated as in Fig. 1. First, various kinases have been
reported to be activated by pathogenic proteins implicated in
different neurodegenerative diseases to phosphorylate kinesin
heavy chain (KHC) or kinesin light chain (KLC), and to affect
anterograde transport [96–99]. The p38 MAP kinase stress pathway
was reported to be activated in mutant SOD1 transgenic mice
[100,101], which potentially provides a connection between mutant
SOD1 and kinesin-mediated axonal transport. Second, elevated Ca2+
levels caused by disrupted calcium homeostasis can promote direct
binding of KHC to Miro and detachment of KHC from microtubules as
discussed earlier [86], which would cause decreased anterograde
axonal transport. Third, our previous studies showed that mutant
SOD1 could interact with the dynein–dynactin complex [68,69],
linking mutant SOD1 to retrograde transport. Fourth, mitochondrial
transport and membrane potential are correlated [102]. Thus, loss of
mitochondrial membrane potential induced by mutant SOD1 as
discussed earlier can be another underlying mechanism. Fifth, mutant
SOD1 aggregation along microtubules may interfere with both
anterograde and retrograde transport like blockades along highways.
Sixth, anterograde and retrograde transport are inter-related and
highly regulated, thus it is not surprising that disruption of the
transport in one direction would affect the transport in the other
direction. Lastly, it is also unclear whether all transported cargos
would be affected similarly or differentially by mutant SOD1. For
instance, a recent study showed that mutant SOD1 interactedwith the
kinesin-2 complex via kinesin-associated protein 3 (KAP3) and
impaired anterograde transport of choline acetyltransferase [70].
Will the axonal transport of mitochondria and of choline acetyl-
transferase be affected in the same fashion in the presence of mutant
SOD1? Or will transport of pro-survival and pro-death signals be
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different organelles, cargos or signals can be differentially altered in
the presence of the ALS-linked SOD1 mutants. Future studies are
needed to clarify how axonal transport of mitochondria is altered in
ALS and to understand the mechanisms.
Despite the unclear mechanism, impaired transport of mitochon-
dria can result in abnormal mitochondrial morphology, redistribution
of mitochondria with fewer mitochondria in axons and nerve
terminals, reduced ATP production from mitochondrial metabolism,
and decreased calcium handling capacity. Moreover, altered mito-
chondrial transport can lead to abnormal mitochondrial dynamics as
discussed in the next section.
9. Potential role of mitochondrial dynamics in ALS
Mitochondria are highly dynamic organelles. Mitochondria are
abundant in areas of active neurons with intense ATP demands such
as the axon hillock, the nodes of Ranvier, and the synaptic regions
[103]. They are actively transported and they can have deﬁned
subcellular distributions that can change rapidly according to
physiological needs. Mitochondria maintain their overall morphology,
distribution and activity through two essential mechanisms, fusion
and ﬁssion. An imbalance of these two opposing processes results in
mitochondrial fragmentation or elongation [104]. It is logical to
speculate that mitochondrial morphology, metabolic function, mem-
brane potential, axonal transport, and ﬁssion and fusion are highly
inter-dependent.
In mammalian cells, the fusion machinery includes Mfn1, Mfn2
and OPA1. Mfn1 and Mfn2 belong to the large GTPase family and
localize to the mitochondrial outer membrane. OPA1 is a dynaminFig. 1. Hypotheses of abnormal axonal transport of mitochondria in ALS. Several
mechanisms by which mutant SOD1 can interfere with axonal transport of
mitochondria have been discussed. (1) Kinesin heavy chain and kinesin light chain
can be phosphorylated by various kinases and anterograde transport would be affected.
(2) Elevated Ca2+ levels can prevent kinesin from binding to microtubules and lead to
decreased anterograde axonal transport. (3) Mutant SOD1 can interact with the
dynein–dynactin complex and may result in impairment of retrograde transport. (4)
Disturbed mitochondrial membrane potential can impact mitochondrial transport. (5)
Aggregation of mutant SOD1 along microtubules may interfere with both anterograde
and retrograde transport like a blockade.family GTPase and localizes within the mitochondrial intermembrane
space. Mfn1 and Mfn2 deletion leads to loss of mitochondrial fusion,
high fragmentation, and correspondingly nomitochondrial tubules. In
addition, Mfn1 and Mfn2 deletion results in severe cellular defects,
including widespread heterogeneity of mitochondrial membrane
potential and decreased cellular respiration [105]. In humans,
mutations in Mfn2 cause Charcot–Marie–Tooth neuropathy type 2A
and mutations in OPA1 cause the most common form of hereditary
optic atrophy [106,107]. On the other hand, the components of
mitochondrial ﬁssion machinery in mammals include Drp1 and Fis1.
Dominant-negative mutants of Drp1 inhibit mitochondrial division
and result in highly interconnected mitochondrial tubules [108].
Overexpression of Fis1 leads to mitochondrial fragmentation, release
of cytochrome c, and ultimately apoptosis [109].
Although no studies have been reported speciﬁcally regarding
mitochondrial ﬁssion and fusion in ALS, abnormal mitochondrial
clustering and fragmentation [31–35] and altered mitochondrial
transport [94,95] are highly suggestive that mitochondrial dynamics
may be inﬂuenced in the presence of mutant SOD1. Changes in
mitochondrial dynamics have been found in other neurodegenerative
diseases such as Alzheimer's disease (AD). Wang et al. found that
mitochondria were much shorter and round in sporadic AD patients'
ﬁbroblasts, indicating imbalance of ﬁssion and fusion [110]. The same
study also found that the levels of dynamin-like protein 1 (Dlp1), a
regulator of mitochondrial ﬁssion and distribution, were decreased
signiﬁcantly in sporadic AD ﬁbroblasts. Wang et al. also reported that
levels of Dlp1 and OPA1 were signiﬁcantly decreased whereas levels
of Fis1 were signiﬁcantly increased in M17 cells overexpressing the
AD-causing APP mutant [111]. Moreover, Dlp1 and OPA1 over-
expression could ameliorate the abnormal mitochondrial morphology
and distribution and synaptic loss induced by oligomeric amyloid-β
derived diffusible ligands [112]. The results provide the best evidence
thus far that APP mutant can cause an imbalance of mitochondrial
ﬁssion/fusion and consequently result in mitochondrial fragmenta-
tion and abnormal distribution. It remains to be determined whether
ALS mutant SOD1 may also impair mitochondrial dynamics.
10. Mitochondria in the “dying back” axonopathy hypothesis of
ALS
Recent studies provide convincing evidence that denervation of
motor neurons from muscles occurs in early stage of the disease
pathogenesis prior to clinical symptoms in mutant SOD1 transgenic
mice [49,50,65,113,114]. A zebraﬁsh model overexpressing mutant
human SOD1 also showed motor neuron axonopathy in a dose-
dependent manner [115]. A “dying-back” axonopathy hypothesis of
ALS thus is emerging in the ﬁeld. Interestingly, transgenic mice with
muscular overexpression of uncoupling protein 1 (UCP1), which only
caused mitochondrial defects in muscles, displayed age-dependent
deterioration of neuromuscular junctions and subsequent motor
neuron pathology [116]. The results are supportive that the distal
pathology at neuromuscular junction can contribute to motor neuron
degeneration in ALS. The results also illustrate the critical importance
of proper function of mitochondria at both the presynaptic and
postsynaptic compartments of the neuromuscular junction. As
discussed earlier, mutant SOD1 may interfere with the mitochondrial
function via multiple mechanisms, particularly via impairment of
mitochondrial transport and dynamics. Thus, maintaining appropriate
population of properly functioning mitochondria in distal axons could
provide a critical therapeutic avenue for potential ALS treatment.
11. Conclusion
It is believed that alterations in multiple pathways in multiple cell
types can contribute to ALS pathogenesis and progression. Mitochon-
drial dysfunction plays a critical role in mutant SOD1 mediated
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functional consequences of mitochondrial dysfunction are discussed
in this review. They include association of mutant SOD1 aggregates
with mitochondria, abnormal mitochondrial morphology, impaired
mitochondrial bioenergetics, loss of mitochondrial membrane poten-
tial, reduced mitochondrial calcium buffering capacity and disrupted
calcium homestasis, impaired axonal transport of mitochondria, and
potential imbalance of mitochondrial ﬁssion and fusion. In fact, many
of the events can be cause for and consequence of each other and they
create a vicious cycle that results in motor axon denervation and
ultimately motor neuron degeneration in ALS.
It is evidently critical to determine the very ﬁrst event induced by
mutant SOD1 and devise a strategy to stop or delay it before the cycle
becomes unstoppable. Misfolding of mutant SOD1 due to the intrinsic
structural properties of the mutation is probably the ﬁrst event. The
impairment of axonal transport by misfolded mutant SOD1 is likely the
immediate next event. The mitochondrial abnormalities can be
secondary effects caused by compromised axonal transport as discussed
in the review. This hypothesis would explain the accumulation of
dysfunctional mitochondria in distal axon terminals and the axon
degeneration that were observed in very early stage of presymptomatic
ALSmice. This speculation is supportive of the “dying back” axonopathy
model that is emerging in the ALS ﬁeld. It is also essential to study the
mechanisms in the context of each other to understand the crosstalk
among the events so that potential therapeutic strategies may be
designed to tackle multiple pathways simultaneously.
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